Chemistry Reference
In-Depth Information
[32] Boström J, Berggren K, Elebring T, Greasley PJ, Wilstermann M. Scaffold hopping,
synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a
novel series of CB1 receptor antagonists. Bioorganic & Medicinal Chemistry
,
2007
,
15:4077-4084.
[33] Hall A, Billinton A, Brown SH, Chowdhury A, Giblin GM, Goldsmith P, Hurst DN, Naylor
A, Patel S, Scoccitti T, Theobald PJ. Discovery of a novel indole series of EP1 receptor
antagonists by scaffold hopping. Bioorganic & Medicinal Chemistry Letters
,
2008,
18:
2684-2690.
[34] Schurer SC, Tyagi P, Muskal SM. Prospective exploration of synthetically feasible,
medicinally relevant chemical space. Journal of Chemical Information and Modeling
,
2005,
45: 239-248.
[35] Gasteiger J.
De novo
design and synthetic accessibility. Journal of Computer-Aided
Molecular Design
,
2007
,
21:307-309, 2007.
[36] Corey EJ, Chelg XM. The logic of chemical synthesis
.
1st ed. New York: John Wiley,
1995. 436 p.
[37] Karpf M. From milligrams to tons: the importance of synthesis and process research in the
development of new drugs. In: Shioiri T, Izawa K, Konoike T. (Ed). Pharmaceutical
process chemistry
.
1st ed. New York: WILEY-VCH Verlag GmbH & Co, 2011. Chapter 1,
p. 01-38.
[38] Wunderlich Z, Mirny LA. Using the topology of metabolic networks to predict viability of
mutant strains. Biophysical Journal, 2006, 91:2304-2311.
[39] Goodwin W. Scientific understanding and synthetic design. British Journal for the
Philosophy of Science
,
2009, 60 271-301.
[40] Patrick GL. An introduction to medicinal chemistry
.
4th ed. Oxford: Oxford University
Press, 2009.
[41] Chauhan PMS, Martins CJA, Horwell DC. Syntheses of novel heterocycles as anticancer
agents. Bioorganic & Medicinal Chemistry
,
2005
,
13:3513-3518.
[42] Brown A, Brown L. Ellis D, Puhalo N, Smith CR, Wallace O, Watson L. Design and
optimization of potent, selective antagonists of oxytocin. Bioorganic & Medicinal
Chemistry Letters, 2008, 18: 4278-4281.
[43] Brown A, Ellis D, Wallace O, Ralph M. Identification of amide bioisosteres of triazole
Oxytocin antagonists. Bioorganic & Medicinal Chemistry Letters
,
2010
,
20:2224-2228.
[44] Manikandan S. Agomelatine: a novel melatonergic antidepressant. Journal of
Pharmacology & Pharmacotherapy
,
2010
,
1
:
122-123.
[45] Millan MJ, Brocco M, Gobert A, Dekeyne, A. Anxiolytic properties of agomelatine, an
antidepressant with melatoninergic and serotonergic properties: role of 5HT
2C
receptor
blockade. Psychopharmacology
,
2005, 177:448-458.
[46] REDDY RESEARCH FOUNDATION (India).Gaddam Om Reddy; Mamillapilli RS,
Chebiyyam P. An improved process for the preparation of melatonin. IN 186858, 24 nov.
2001.
[47]
SERVIER LABORATORIES (France). Jean-Claude S, Isaac GB, Gilles T, Genevieve C,
Stephane H, Gerard D. Process for the synthesis and crystalline form of agomelatine. US
7498466, 03 jan. 2008.
[48]
Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide:
characterization of the form of cytochrome P-450 involved in methyl hydroxylation and
